Literature DB >> 22210668

Ocular manifestations as key features for diagnosing mucopolysaccharidoses.

C Gail Summers1, Jane L Ashworth.   

Abstract

Diagnosis of mucopolysaccharidosis (MPS) requires awareness of the multisystem disease manifestations and their diverse presentation in terms of time of onset and severity. Many patients with MPS remain undiagnosed for years and progressively develop irreversible pathologies, which ultimately lead to premature death. To foster timely treatment and ensure a better outcome, it is of utmost importance to recognize and evaluate the typical ocular features that present fairly early in the course of the disease in many children with MPS. These include corneal clouding, ocular hypertension/glaucoma, retinal degeneration, optic disc swelling and optic nerve atrophy. Other associations include pseudo-exophthalmos, amblyopia, strabismus and large refractive errors requiring spectacle correction. While some ocular manifestations require specialized equipment for detecting abnormalities, light sensitivity, pseudo-exophthalmos and strabismus are often apparent on a routine physical examination. In addition, patients may be symptomatic from vision impairment, photosensitivity, night blindness and visual field constriction. Combined with the skeletal/joint complications and other manifestations, these ocular features are key in the differential diagnosis of children with joint abnormalities. Rheumatologists should have a high index of suspicion for MPS to facilitate early diagnosis. Referral to a geneticist, a metabolic specialist or physician who specializes in MPS can confirm the diagnosis and provide disease management. Consultation with an ophthalmologist who has expertise in MPS is also needed for thorough examination of the eyes and regular follow-up care.

Entities:  

Mesh:

Year:  2011        PMID: 22210668     DOI: 10.1093/rheumatology/ker392

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  17 in total

1.  Spectral domain optical coherence tomography imaging of mucopolysaccharidoses I, II, and VI A.

Authors:  Susie Seok; In Jeong Lyu; Kyung Ah Park; Sei Yeul Oh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-02-18       Impact factor: 3.117

Review 2.  Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA.

Authors:  C J Hendriksz; P Harmatz; M Beck; S Jones; T Wood; R Lachman; C G Gravance; T Orii; S Tomatsu
Journal:  Mol Genet Metab       Date:  2013-04-10       Impact factor: 4.797

3.  Compound heterozygous missense mutations in a Chinese mucopolysaccharidosis type VI patient: a case report.

Authors:  Ming-Fang He; Ji Yang; Meng-Jie Dong; Yin-Ting Wang; Hai Liu
Journal:  BMC Ophthalmol       Date:  2021-05-13       Impact factor: 2.209

Review 4.  International guidelines for the management and treatment of Morquio A syndrome.

Authors:  Christian J Hendriksz; Kenneth I Berger; Roberto Giugliani; Paul Harmatz; Christoph Kampmann; William G Mackenzie; Julian Raiman; Martha Solano Villarreal; Ravi Savarirayan
Journal:  Am J Med Genet A       Date:  2014-10-24       Impact factor: 2.802

5.  Comparison of Rebound Tonometry, Perkins Applanation Tonometry and Ocular Response Analyser in Mucopolysaccharidosis Patients.

Authors:  Joanna Wasielica-Poslednik; Christina Butsch; Christina Lampe; Heike Elflein; Julia Lamparter; Veronika Weyer; Susanne Pitz
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

6.  Influence of Corneal Opacity on Intraocular Pressure Assessment in Patients with Lysosomal Storage Diseases.

Authors:  Joanna Wasielica-Poslednik; Giuseppe Politino; Irene Schmidtmann; Katrin Lorenz; Katharina Bell; Norbert Pfeiffer; Susanne Pitz
Journal:  PLoS One       Date:  2017-01-12       Impact factor: 3.240

7.  Posterior fossa horns; a new calvarial finding of mucopolysaccharidoses with well-known cranial MRI features.

Authors:  Çağri Damar; Betül Emine Derinkuyu; Muazzez Asburçe Bike Olgaç Kiliçkaya; Mehmet Öztürk; Çiğdem Öztunali; Ayşe Gül Alimli; Öznur Leman Boyunaga; Murat Uçar; Fatih Süheyl Ezgü; Leyla Tümer; Alp Özgün Börcek; Ahmet Siğirci
Journal:  Turk J Med Sci       Date:  2020-02-03       Impact factor: 0.973

8.  Diagnosing mucopolysaccharidosis IVA.

Authors:  Timothy C Wood; Katie Harvey; Michael Beck; Maira Graeff Burin; Yin-Hsiu Chien; Heather J Church; Vânia D'Almeida; Otto P van Diggelen; Michael Fietz; Roberto Giugliani; Paul Harmatz; Sara M Hawley; Wuh-Liang Hwu; David Ketteridge; Zoltan Lukacs; Nicole Miller; Marzia Pasquali; Andrea Schenone; Jerry N Thompson; Karen Tylee; Chunli Yu; Christian J Hendriksz
Journal:  J Inherit Metab Dis       Date:  2013-02-01       Impact factor: 4.982

9.  Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery.

Authors:  Haiyan Fu; Marcela P Cataldi; Tierra A Ware; Kimberly Zaraspe; Aaron S Meadows; Darren A Murrey; Douglas M McCarty
Journal:  Mol Ther Methods Clin Dev       Date:  2016-06-08       Impact factor: 6.698

Review 10.  Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.

Authors:  Christiane S Hampe; Julie B Eisengart; Troy C Lund; Paul J Orchard; Monika Swietlicka; Jacob Wesley; R Scott McIvor
Journal:  Cells       Date:  2020-08-05       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.